[
    [
        {
            "time": "",
            "original_text": "【科创板大阅兵】多家A股药企是客户，美迪西研发人员占总员工81%，还在招兵买马！",
            "features": {
                "keywords": [
                    "科创板",
                    "A股药企",
                    "美迪西",
                    "研发人员",
                    "招兵买马"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "【科创板大阅兵】多家A股药企是客户，美迪西研发人员占总员工81%，还在招兵买马！",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "瑞银：升药明康德(02359.HK)目标价至121.76港元 评级“买入”",
            "features": {
                "keywords": [
                    "瑞银",
                    "药明康德",
                    "目标价",
                    "买入"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "瑞银：升药明康德(02359.HK)目标价至121.76港元 评级“买入”",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "药明康德:业绩保持高增长,一体化、端到端赋能平台价值凸显",
            "features": {
                "keywords": [
                    "药明康德",
                    "高增长",
                    "一体化",
                    "端到端",
                    "赋能平台"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "药明康德:业绩保持高增长,一体化、端到端赋能平台价值凸显",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]